Drug General Information (ID: DDIRPH7BX8)
Drug Name			Strontium chloride Sr-89		Drug Info		Belantamab mafodotin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Therapeutic Radiopharmaceuticals				Antineoplastics

Mechanism of Strontium chloride Sr-89-Belantamab mafodotin Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Strontium chloride Sr-89				Belantamab mafodotin
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Strontium chloride Sr-89 and Belantamab mafodotin

Recommended Action
Management		Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Multum Information Services, Inc. Expert Review Panel.